-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on Maze Therapeutics, Maintains $46 Price Target

Benzinga·03/25/2026 17:35:14
Listen to the news
BTIG analyst Julian Harrison reiterates Maze Therapeutics (NASDAQ:MAZE) with a Buy and maintains $46 price target.